Dominant-negative SOX9 mutations in campomelic dysplasia.

TitleDominant-negative SOX9 mutations in campomelic dysplasia.
Publication TypeJournal Article
Year of Publication2019
AuthorsCsukasi, F, Duran, I, Zhang, W, Martin, JH, Barad, M, Bamshad, M, Weis, MAnn, Eyre, D, Krakow, D, Cohn, DH
JournalHum Mutat
Volume40
Issue12
Pagination2344-2352
Date Published2019 12
ISSN1098-1004
Abstract

Campomelic dysplasia (CD) is an autosomal dominant, perinatal lethal skeletal dysplasia characterized by a small chest and short long bones with bowing of the lower extremities. CD is the result of heterozygosity for mutations in the gene encoding the chondrogenesis master regulator, SOX9. Loss-of-function mutations have been identified in most CD cases so it has been assumed that the disease results from haploinsufficiency for SOX9. Here, we identified distal truncating SOX9 mutations in four unrelated CD cases. The mutations all leave the dimerization and DNA-binding domains intact and cultured chondrocytes from three of the four cases synthesized truncated SOX9. Relative to CD resulting from haploinsufficiency, there was decreased transactivation activity toward a major transcriptional target, COL2A1, consistent with the mutations exerting a dominant-negative effect. For one of the cases, the phenotypic consequence was a very severe form of CD, with a pronounced effect on vertebral and limb development. The data identify a novel molecular mechanism of disease in CD in which the truncated protein leads to a distinct and more significant effect on SOX9 function.

DOI10.1002/humu.23888
Alternate JournalHum. Mutat.
PubMed ID31389106
Grant ListRO1 AR066124 / RG / CSR NIH HHS / United States
R01 AR062651 / RG / CSR NIH HHS / United States
NIH HG006493 / RG / CSR NIH HHS / United States
RO1 DE019567 / RG / CSR NIH HHS / United States
RO1 AR066124 / RG / CSR NIH HHS / United States
R01 AR062651 / RG / CSR NIH HHS / United States
NIH HG006493 / RG / CSR NIH HHS / United States
RO1 DE019567 / RG / CSR NIH HHS / United States